DREAMM-2: Exploration of BCVA, Ocular Symptoms, and OSDI Questionnaire as Surrogates for Corneal Alterations During Treatment With Belantamab Mafodotin in R/R MM

June 4-8, 2021; Online at https://conferences.asco.org/am
Post-hoc analysis of the DREAMM-2 findings suggest that BCVA changes and patient-reported ocular symptoms are concordant with corneal exam findings after belantamab mafodotin treatment in the majority of cases.
Format: Microsoft PowerPoint (.ppt)
File Size: 457 KB
Released: June 5, 2021


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Novartis Pharmaceuticals Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.
Sanofi Genzyme

Related Content

Experts review key data for multiple myeloma at the 2021 hematology annual meeting, from Clinical Care Options (CCO)

Shaji K. Kumar, MD Sagar Lonial, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: May 12, 2022 Expired: May 11, 2023

Rebecca Gonzalez, PharmD, BCOP, discusses key pharmacy strategies for management of patients with multiple myeloma in this commentary from Clinical Care Options (CCO)

Rebecca Gonzalez, PharmD, BCOP Released: May 6, 2022

PDF resource that serves as a helpful guide for healthcare professionals on BCMA-targeted therapies in multiple myeloma, from Clinical Care Options (CCO)

Released: May 2, 2022

On-demand webcast on CAR T-cells for patients with hematologic malignancies, from Clinical Care Options (CCO)

Craig Freyer, PharmD, BCOP Andrew Lin, PharmD, BCOP Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 28, 2022 Expired: April 27, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings